Ipsen’s Partner Roche Says Taspoglutide Meets Endpoint in Phase III Trial

Ipsen, a global biopharmaceutical group, Thursday announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 analogue based on a human sequence.
MarketWatch